Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle

Leibovitz S, Meshorer A, Fridman Y, Wieneke S, Jockusch H, Yaffe D, Nudel U (2002)
NEUROMUSCULAR DISORDERS 12(9): 836-844.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ;
Abstract
Dystrophin, the protein which is absent or non-functional in Duchenne muscular dystrophy, consists of four main domains: an N-terminal actin binding domain, a rod shaped domain of spectrin-like repeats, a cysteine-rich domain and a unique C-terminal domain. In muscle, dystrophin forms a linkage between the cytoskeletal actin and a group of membrane proteins (dystrophin associated proteins). The N-terminal domain binds to the cytoskeletal actin and the association with the dystrophin associated proteins is mediated mainly by the cysteine-rich and C-terminal domains of dystrophin. The dystrophin gene also encodes two isoforms of non-muscle dystrophins and a number of smaller products consisting of the two C-terminal domains with different extensions into the spectrin-like repeat domain. Dp71, which consist of the C-terminal and the cysteine-rich domains of dystrophin, is the major product of the gene in all non-muscle tissues tested so far, but it is absent in differentiated skeletal muscle. In an attempt to understand the functions of Dp71, we produced transgenic mice over-expressing this protein in several tissues. The highest levels of exogeneous Dp71 were detected in skeletal muscle, in association with the sarcolemma. This resulted in muscle damage similar to that found in mice which lack dystrophin. The data indicates that Dp71 competes with dystrophin for the binding to the dystrophin associated proteins. Since Dp71 lacks the actin binding domain, it cannot form the essential linkage between the dystrophin associated proteins complex and the cytoskeleton. (C) 2002 Elsevier Science B.V. All rights reserved.
Publishing Year
ISSN
PUB-ID

Cite this

Leibovitz S, Meshorer A, Fridman Y, et al. Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle. NEUROMUSCULAR DISORDERS. 2002;12(9):836-844.
Leibovitz, S., Meshorer, A., Fridman, Y., Wieneke, S., Jockusch, H., Yaffe, D., & Nudel, U. (2002). Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle. NEUROMUSCULAR DISORDERS, 12(9), 836-844.
Leibovitz, S., Meshorer, A., Fridman, Y., Wieneke, S., Jockusch, H., Yaffe, D., and Nudel, U. (2002). Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle. NEUROMUSCULAR DISORDERS 12, 836-844.
Leibovitz, S., et al., 2002. Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle. NEUROMUSCULAR DISORDERS, 12(9), p 836-844.
S. Leibovitz, et al., “Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle”, NEUROMUSCULAR DISORDERS, vol. 12, 2002, pp. 836-844.
Leibovitz, S., Meshorer, A., Fridman, Y., Wieneke, S., Jockusch, H., Yaffe, D., Nudel, U.: Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle. NEUROMUSCULAR DISORDERS. 12, 836-844 (2002).
Leibovitz, S, Meshorer, A, Fridman, Y, Wieneke, S, Jockusch, Harald, Yaffe, D, and Nudel, U. “Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle”. NEUROMUSCULAR DISORDERS 12.9 (2002): 836-844.
This data publication is cited in the following publications:
This publication cites the following data publications:

7 Citations in Europe PMC

Data provided by Europe PubMed Central.

Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy.
McGreevy JW, Hakim CH, McIntosh MA, Duan D., Dis Model Mech 8(3), 2015
PMID: 25740330
Upregulation of brain utrophin does not rescue behavioral alterations in dystrophin-deficient mice.
Perronnet C, Chagneau C, Le Blanc P, Samson-Desvignes N, Mornet D, Laroche S, De La Porte S, Vaillend C., Hum. Mol. Genet. 21(10), 2012
PMID: 22343141
Dystrophin Dp71: the smallest but multifunctional product of the Duchenne muscular dystrophy gene.
Tadayoni R, Rendon A, Soria-Jasso LE, Cisneros B., Mol. Neurobiol. 45(1), 2012
PMID: 22105192
Transgenic overexpression of dystroglycan does not inhibit muscular dystrophy in mdx mice.
Hoyte K, Jayasinha V, Xia B, Martin PT., Am. J. Pathol. 164(2), 2004
PMID: 14742274
Muscular dystrophy with truncated dystrophin in a family of Japanese Spitz dogs.
Jones BR, Brennan S, Mooney CT, Callanan JJ, McAllister H, Guo LT, Martin PT, Engvall E, Shelton GD., J. Neurol. Sci. 217(2), 2004
PMID: 14706216
A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration.
Weir AP, Morgan JE, Davies KE., Neuromuscul. Disord. 14(1), 2004
PMID: 14659408

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 12398834
PubMed | Europe PMC

Search this title in

Google Scholar